Cargando…

Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis

INTRODUCTION: Together with agranulocytosis, fever and immflamatory manifestations are clozapine side effects to be monitorized during initial treatment. In the context of COVID-19 pandemic, implied mechanisms, and symptomatology should be carefully controlled. OBJECTIVES: To analyze the clinical an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelayo-Terán, J.M., Zapico-Merayo, Y., Vega-García, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567427/
http://dx.doi.org/10.1192/j.eurpsy.2022.1298
_version_ 1784809395265208320
author Pelayo-Terán, J.M.
Zapico-Merayo, Y.
Vega-García, S.
author_facet Pelayo-Terán, J.M.
Zapico-Merayo, Y.
Vega-García, S.
author_sort Pelayo-Terán, J.M.
collection PubMed
description INTRODUCTION: Together with agranulocytosis, fever and immflamatory manifestations are clozapine side effects to be monitorized during initial treatment. In the context of COVID-19 pandemic, implied mechanisms, and symptomatology should be carefully controlled. OBJECTIVES: To analyze the clinical analytic and inflammatory chracterisctics the resembles and differenciates clozapine immune response and SARS-CoV-2 infection. To describe a case of clozapine induced fever and pneumonitis during COVID-19 pandemic. METHODS: A case of clozapine-induced pneumonitis during COVID-19 pandemic is described.- A mini-review of clozapine inflamamtory effects, induced-pneumonitis and SARS-CoV-2 was performed. RESULTS: A 33 year old afrolatin male started treatment with clozapine up to 250 mg daily. He developed fever and respiratory symptoms in the 11th day of treatment. The exploration revealed pulmonary sounds decreased and 91% basal saturation, making the probable causes viral infection (local incidence of SARS-CoV-2 >800/100000hab), nosocomial bacterial infection or pulmonary thromboembolism. The patient was isolated due to probable COVID-19. Blood tests showed leucocytosis (13400/mcL), Lymphocytopenia (11.8%), high PCR (14.4mg/dL), Ferritine (506.9ng/mL), Fibrinigen (663.83 mg/dL), D-Dimer (1.61mg/dL), and Interleukin-9 /25.8pg/mL). The angioTC revealed a pleural efusion and ground glass infiltrates (figure1). Only after 2 weeks eosinophilia was discovered (88/mcL) After 2 negative consecutieve PCRs for SARS-CoV-2, no imrovement with ampirical antibiotics and all infectious pannels negative, we started decreasing clozapine with improvement of the symptoms and resolution after suspending clozapine completely. [Figure: see text] CONCLUSIONS: Clozapine may induce a generalize inflammatory response mediated by interleukin-6. Patients treated with clozapine may exhibit fever and rarely, insterstitial lung inflammation. The expression of induced pneumonitis resembles viral infections, particularly SARS-CoV-2 DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9567427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95674272022-10-17 Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis Pelayo-Terán, J.M. Zapico-Merayo, Y. Vega-García, S. Eur Psychiatry Abstract INTRODUCTION: Together with agranulocytosis, fever and immflamatory manifestations are clozapine side effects to be monitorized during initial treatment. In the context of COVID-19 pandemic, implied mechanisms, and symptomatology should be carefully controlled. OBJECTIVES: To analyze the clinical analytic and inflammatory chracterisctics the resembles and differenciates clozapine immune response and SARS-CoV-2 infection. To describe a case of clozapine induced fever and pneumonitis during COVID-19 pandemic. METHODS: A case of clozapine-induced pneumonitis during COVID-19 pandemic is described.- A mini-review of clozapine inflamamtory effects, induced-pneumonitis and SARS-CoV-2 was performed. RESULTS: A 33 year old afrolatin male started treatment with clozapine up to 250 mg daily. He developed fever and respiratory symptoms in the 11th day of treatment. The exploration revealed pulmonary sounds decreased and 91% basal saturation, making the probable causes viral infection (local incidence of SARS-CoV-2 >800/100000hab), nosocomial bacterial infection or pulmonary thromboembolism. The patient was isolated due to probable COVID-19. Blood tests showed leucocytosis (13400/mcL), Lymphocytopenia (11.8%), high PCR (14.4mg/dL), Ferritine (506.9ng/mL), Fibrinigen (663.83 mg/dL), D-Dimer (1.61mg/dL), and Interleukin-9 /25.8pg/mL). The angioTC revealed a pleural efusion and ground glass infiltrates (figure1). Only after 2 weeks eosinophilia was discovered (88/mcL) After 2 negative consecutieve PCRs for SARS-CoV-2, no imrovement with ampirical antibiotics and all infectious pannels negative, we started decreasing clozapine with improvement of the symptoms and resolution after suspending clozapine completely. [Figure: see text] CONCLUSIONS: Clozapine may induce a generalize inflammatory response mediated by interleukin-6. Patients treated with clozapine may exhibit fever and rarely, insterstitial lung inflammation. The expression of induced pneumonitis resembles viral infections, particularly SARS-CoV-2 DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567427/ http://dx.doi.org/10.1192/j.eurpsy.2022.1298 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Pelayo-Terán, J.M.
Zapico-Merayo, Y.
Vega-García, S.
Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis
title Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis
title_full Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis
title_fullStr Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis
title_full_unstemmed Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis
title_short Clozapine Toxicity in the Setting of COVID-19: A case of differential diagnosis
title_sort clozapine toxicity in the setting of covid-19: a case of differential diagnosis
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567427/
http://dx.doi.org/10.1192/j.eurpsy.2022.1298
work_keys_str_mv AT pelayoteranjm clozapinetoxicityinthesettingofcovid19acaseofdifferentialdiagnosis
AT zapicomerayoy clozapinetoxicityinthesettingofcovid19acaseofdifferentialdiagnosis
AT vegagarcias clozapinetoxicityinthesettingofcovid19acaseofdifferentialdiagnosis